Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NBSE - NeuBase Therapeutics Inc

Close
0.378
-0.013   -3.307%

Share volume: 97,744
Last Updated: Fri 10 May 2024 10:00:00 PM CEST
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%
$0.39
-0.01
-3.20%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
49%
Profitability 50%
Dept financing 3%
Liquidity 46%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-30.22%
1 Month
-42.26%
3 Months
-73.77%
6 Months
-80.96%
1 Year
-96.24%
2 Year
-98.69%
Key data
Stock price
$0.38
P/E Ratio 
0.00
DAY RANGE
$0.36 - $0.39
EPS 
$0.00
52 WEEK RANGE
$0.80 - $26.60
52 WEEK CHANGE
-$0.96
MARKET CAP 
32.796 M
YIELD 
N/A
SHARES OUTSTANDING 
33.810 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.43
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$614,941
AVERAGE 30 VOLUME 
$234,902
Company detail
CEO: Dietrich Stephan
Region: US
Website: https://www.neubasetherapeutics.com/
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

neubase has developed a modular antisense technology platform with the capability to address any rare genetic disease caused by mutant proteins with a single, cohesive approach. neubase's platform improves upon gene silencing therapies by combining the advantages of synthetic approaches with the precision of antisense technologies. neubase plans to use its unparalleled antisense platform to address both repeat expansion disorders, with an initial focus on huntington's disease and myotonic dystrophy, and dominant genetic disorders.

Recent news